Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.63USD
19 Sep 2017
Change (% chg)

-- (--)
Prev Close
$1.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
132,000
52-wk High
$1.89
52-wk Low
$0.74

Latest Key Developments (Source: Significant Developments)

Durect Q2 loss per share $0.07
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Durect Corp :Durect Corporation announces second quarter 2017 financial results and provides corporate update.Q2 revenue $4.3 million.Q2 revenue view $3.4 million -- Thomson Reuters I/B/E/S.Qtrly loss per share $0.07.Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​
Friday, 28 Jul 2017 04:25pm EDT 

July 28 (Reuters) - Durect Corp :Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​.Durect Corp - termination returns to durect development and commercialization rights to Eladur(transdur)-bupivacaine) - SEC filing.  Full Article

Durect completes enrollment in persist, phase 3 trial for Posimir
Thursday, 22 Jun 2017 07:00am EDT 

June 22 (Reuters) - Durect Corp :Durect completes enrollment in Persist, phase 3 trial for Posimir.Durect - Durect remains responsible for completion of ongoing persist phase 3 clinical trial for Posimir as well as FDA interactions through approval.Durect Corp - phase 3 trial for Posimir top-line data on track for Q4 2017.  Full Article

Durect's collaboration with Sandoz clears HSR review
Monday, 19 Jun 2017 07:00am EDT 

June 19 (Reuters) - Durect Corp::Durect's collaboration with Sandoz clears Hart-Scott-Rodino review and is effective.Durect Corporation - development and commercialization agreement with Sandoz AG to develop and market in U.S. Durect's Posimir has cleared Hart-Scott-Rodino review.  Full Article

Durect Corp, Sandoz AG sign U.S. development and commercialization agreement for posimir
Thursday, 11 May 2017 08:45am EDT 

May 11 (Reuters) - Durect Corp :Durect Corp - co and Sandoz AG, a division of Novartis, have signed a development and commercialization agreement for U.S. for posimir.Durect Corp - under terms of agreement, Sandoz will make an upfront payment to Durect of $20 million.Durect Corp - co remain's responsible for conducting persist Phase 3 trial, comparing posimir to bupivacaine HC1 after laparoscopic gall bladder removal.Durect Corp - company anticipates completing dosing patients in Q3/17 for persist Phase 3 trial and expects to have top-line data shortly thereafter.Durect - deal also includes potential for up to additional $43 million in development, regulatory milestones, up to additional $230 million in sales based milestones.  Full Article

Durect Q1 revenue $4.6 million
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Durect Corp :Durect Corporation announces first quarter 2017 financial results and provides corporate update.Q1 revenue $4.6 million.Durect Corp - Qtrly net loss per share $ 0.06.Durect Corp- At March 31, 2017, cash and investments were $16.8 million, compared to cash and investments of $25.2 million at December 31, 2016.  Full Article

Durect and Sandoz signs a $293 mln development and commercialization agreement for Posimir
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Durect Corp : :Durect and Sandoz have signed a $293 million development and commercialization agreement for Posimir (saber-bupivacaine) covering the United States.Durect Corp - Durect will remain responsible for completion of ongoing persist phase 3 clinical trial for posimir as well as fda interactions through approval.  Full Article

Durect presents data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH)
Monday, 24 Apr 2017 08:00am EDT 

April 24 (Reuters) - Durect Corp :Durect announces presentation of data from a Phase 1B study of DUR-928 in nonalcoholic steatohepatitis (NASH).DUR-928 was well tolerated in study.Additional studies, including larger controlled trials, will be required to confirm findings.Durect - reduction of biomarkers, results from animal, cell culture studies suggest potential therapeutic activity of DUR-928 in patients with liver disease.  Full Article

Durect Corporation posts Q4 loss per share $0.06
Tuesday, 14 Mar 2017 04:02pm EDT 

Durect Corp : Durect Corporation announces fourth quarter and full year 2016 financial results and update of programs . Q4 revenue $3.5 million versus I/B/E/S view $3.6 million .Qtrly loss per share $0.06.  Full Article

Durect Corp qtrly loss per share $0.07
Monday, 1 Aug 2016 04:05pm EDT 

Durect Corp : Durect corporation announces second quarter 2016 financial results and update of programs . Q2 revenue $3.2 million versus i/b/e/s view $3.7 million . Qtrly loss per share $0.07 .Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Durect Q2 loss per share $0.07

* Durect Corporation announces second quarter 2017 financial results and provides corporate update